Endothelial Progenitor Cells and Pulmonary Idiopathic Arterial Hypertension

Unidad de Investigacion Clinica en Medicina S.C.

Status: Completed

Conditions: Pulmonary Idiopathic Arterial Hypertension

Study type: Observational

Funder types: NETWORK

Identifiers

NCT00551408

UDICEM07-012

07-012

Details and patient eligibility

About

Endothelial dysfunction ultimately represents an imbalance between the magnitude of injury and the capacity for repair.

Current evidence established that endothelial progenitor cells (EPC) participate in several models of vascular disease as acute coronary syndromes, stroke, diabetes, peripheral artery disease, etc. However EPC in the setting of PAH is less well established. The target of this study is to demonstrate if the number of EPC is increased in a mexican population of patients with PAH.

Enrollment: 20 patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients were included in the study if they were in The WHO functional class II to III, and had a mean pulmonary artery pressure >30 mm Hg on right heart catheterization. The ability to walk >50 m during a standardized 6-min walk test.

Exclusion criteria

• Pulmonary hypertension as a result of heart disease, pulmonary disease, sleep-associated disorders, chronic thromboembolic disease, autoimmune or collagen vascular disease, HIV infection, liver disease, major bleeding requiring blood transfusion,renal dysfunction, and evidence for malignant diseases were excluded.

Trial design

20 participants in 1 patient group

A

Description:

20 patients with idiopathic pulmonary arterial hypertension in the WHO functional class II to III, and had a mean pulmonary artery pressure \>30 mm Hg on right heart catheterization able to walk \>50 m during a standardized 6-min walk test.